Differently, is consistent with available literature describing that TP53 comutations show a remarkable benefit of PD-L1 blockade, likely derived from a TP53-related increase in PD-L1 expression and a greater infiltration of CD8+ T-cells in lung adenocarcinomas [30]. This evidence concerns the gene CD8A and lung adenocarcinoma.